Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors
S. Pedraza-Arevalo, E. Alors-Perez, R. Blazquez-Encinas, A. D. Herrera-Martinez, J. M. Jimenez-Vacas, A. C. Fuentes-Fayos, O. Reyes, S. Ventura, R. Sanchez-Sanchez, R. Ortega-Salas, R. Serrano-Blanch, M. A. Galvez-Moreno, M. D. Gahete, A. Ibanez-Costa, R. M. Luque, J. P. Castano
The paper identifies NOVA1 as a therapeutic target in PanNETs by showing its role in splicing dysregulation, cell proliferation, and drug resistance.
bioRxiv · Feb 9, 2022 · PreprintCancer Biology